2020年8月17日
Teva, Cipla Appear to Settle Generic Delay Suit Over Sensipar
PDFをダウンロード
To read complete article visit Bloomberg Law (subscription required)
Cipla Ltd. dropped an antitrust lawsuit against Teva Pharmaceutical Industries Ltd., following an apparent settlement of claims in Delaware federal court that Teva stopped selling its generic version of Amgen Inc.'s blockbuster calcium reducer Sensipar because of an anti-competitive patent deal.
